CGON

79.4702.97%
AK

Arthur Kuan

President, Chairman & CEO

Mr. Arthur Kuan serves as Chief Executive Officer and Director at CG Oncology, Inc. since 2017 and also serves as Chairman since December 2023 He serves as President at CG Oncology Inc. since May 2026. Mr. Kuan served as the Chief Operating Officer of CG Oncology, Inc. and served as its Vice President of Research and Clinical Project Management since July 30, 2014. Mr. Kuan was a Founding Member of Ally Bridge Group. Mr. Kuan has served on the board of directors of Chunghwa Chemical Synthesis & Biotech (TPEX: 1762), a Taiwanese manufacturer and distributor of chemical synthetic products and biotechnology products, since 2022, where he serves on its compensation committee and audit committee. He had been a Director of CG Oncology, Inc. since August 5, 2015. Previously, he was a member of Themes Investment Partners where he played a central role in coordinating cross-border technology transfer and regulatory submissions for portfolio companies. He began his career in an operational role at Dinova Capital.From 2016 to 2023, he served on the board of directors of Allied Industrial Corp., Ltd. (TPEX: 4702), a leading supplier of disperse dyestuff. He received his M.S. in Biotechnology from the Johns Hopkins University and his B.A. in Biology from the University of Pennsylvania.

Positions